Jacob Calmvik, Co-Founder and CEO of Avia, comments: “We are thrilled to welcome Neubourg to Avia. The acquisition fits perfectly with our strategy of acquiring strong local brands, such as Allpresan, in the DACH region.”

“I believe Avia will be a very strong long-term owner of Neubourg and that they will be able to develop our brands further. The Neubourg portfolio also complements Avia’s current dermatology portfolio in a good way. I am very pleased we have been able to reach this agreement.”, says Thomas Neubourg, CEO and co-owner of Neubourg.

For further information, please contact:
Jacob Calmvik, CEO of Avia,  jacob.calmvik@aviapharma.se

About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/

About Neubourg
Neubourg was founded in 1998 and is a German dermatology company with brands such as Allpresan, Podoexpert and Onyfix. It has built its market position via proprietary technology and is recognized by pharmacies and consumers as the market leader in its niches. Learn more about Neubourg at www.neubourg.com     

The partnership with Impilo will allow Avia to execute on its strategy and ambition of building a leading Northern European OTC / Rx platform through organic and inorganic growth.

Avia was founded in 2016 and focuses on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products. The Company has successfully executed on its strategy to build its own brand portfolio and to grow its Northern European presence over time, through a combination of M&A (6 since inception), in-licensing of additional products and growing market share across the portfolio. Avia is today a well-diversified platform present across the Nordics and Germany with headquarters in Stockholm, Sweden, and with offices in Germany and Finland.

Jacob Calmvik, Co-Founder and CEO of Avia, comments: “The partnership with Impilo is an important step for Avia and will enable us to fully execute on our strategy. Together with Impilo we will continue to scale the platform at a high pace through organic and inorganic growth initiatives. Further, we are happy to welcome Per Edelmann, who comes with vast industry experience, as the new chairperson of the board.”

As a testament to the ambitious growth agenda, in the week after Impilo closed its investment in Avia, the Company closed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition of Neubourg, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market leader in foam-based foot care.

“Impilo is very excited to partner with Avia management and the co-founders Jacob Calmvik and Jostein Lønberg. We have followed Avia’s growth journey closely and look forward to supporting the Company in its effort to build a leading platform in the OTC/Rx space”, says Carolina Oscarius Dahl, Partner at Impilo

For further information, please contact:
Jacob Calmvik, CEO of Avia,  jacob.calmvik@aviapharma.se
Carolina Oscarius Dahl, Partner at Impilo,  carolina.oscarius.dahl@impilo.se

About Avia Pharma
Avia is a leading Swedish OTC/Rx distribution platform with presence in the Nordics and Germany, focusing on medically positioned products within dermatology, allergy, women’s health, urology and general OTC products with brands such as Nix, Duroferon and Allergika. With the most recent acquisition of Neubourg, Avia has an annual turnover of more than SEK 600m. Learn more about Avia Pharma at www.aviapharma.se/

About Impilo
Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare and care services, and other health-related areas. The Company strives to increase the value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and has raised c. SEK 10 billion in capital from leading Nordic and international investors since its inception in 2017. Learn more about Impilo at www.impilo.se/en/

“The acquisition allows us to continue offering this complement to D-vitamin oil”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please contact Marie Wikman, marie.wikman@aviapharma.se, +46 708 16 88 16.

Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.

75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.

Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.

In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains. “In addition Nyvigan offers no systemic exposure, no known drug interactions and can be used during any stage of pregnancy and breast-feeding”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please contact Marie Wikman, marie.wikman@aviapharma.se, +46 708 16 88 16.

“The acquisition is in line with Avia Pharma’s strategy to own more products and will complement our existing portfolio”, says Jacob Calmvik, CEO of Avia Pharma.

For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703 70 71 69

Allergika is a German pharmaceutical company focused on the allergy market. It sells both dermatology products and encasing under its own brands.

The dermatology products have, in terms of market share, a very strong position in the medical cosmetics market in Germany and have experienced very high growth rates. 

“By acquiring Allergika, we are taking a big step towards realizing our strategy of building a northern European pharmaceutical company. This deal gives us a great platform for further expansion in the DACH region. Allergika’s products are very well known throughout the medical community, especially among dermatologist and allergologists as well as pharmacists and the products are very appreciated by patients in Germany. We will continue to build upon Allergika’s strong market position and further develop the company” says Jacob Calmvik, CEO of Avia Pharma

For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703 70 71 69

Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur.

The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part of its strategy to build a northern European pharmaceutical company.

“I am really pleased to be able to announce this deal today. Decem Pharma has over the years built a very strong position in Finland with several strong brands. Decem Pharma will strengthen our presence in Finland considerably and enable us to improve the performance of the group’s products in Finland. The current management will continue to run this successful business, but we will of course make sure to extract both sales and cost synergies” says Jacob Calmvik, CEO of Avia Pharma

“Decem Pharma is excited to join forces with Avia Pharma and continue to expand the business in both Finland and abroad. The deal made strategic sense and we will be able to reap significant benefits from it” says Erno Lehtovirta, Chairman of Decem Pharma    For further information, contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se

-Avia Pharma continues its expansion and the acquisition of Pharmaprim means that we will be able to work with products that complement Avia Pharma´s existing portfolio. Through the acquisition, we strengthen our position both in prescription as well as non-prescription drugs within women´s and men´s health. Both companies have presence in the Nordic countries, which also results in both cost and sales synergies, says Jacob Calmvik, CEO of Avia Pharma.

Avia Pharma currently promotes, among other products, Intrarosa for vaginal atrophy. Intrarosa is a local treatment, new in its kind, with DHEA as active substance. DHEA is converted to both estrogen and testosterone in the vagina.

Pharmaprim is a privately owned pharmaceutical company based in Stockholm and operating in the Nordic region. The company has a sale of approx. 15 million SEK.

-Avia Pharmas value base and strategy are well in line with Pharmaprim´s future ambitions and together we see great potential in continuing our joint growth journey, says Kjell Legernaes, former CEO of Pharmaprim, who now assumes the role of Business Director Urology at Avia Pharma.

-We are particularly pleased to be the owner of two high quality Perrigo products. The acquisition is fully in line with our goal of owning products both within self-care products as well as within prescription drugs, says Jacob Calmvik, CEO of Avia Pharma.

ACO Karbamid and ACO Glycerol will be renamed Curemid and Cremarol in the fall of 2020. The products are now registered only in Sweden, but are expected to be registered in additional countries.